• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Prasinezumab therapy does not affect Parkinson’s Disease progression

byDavid XiangandKiera Liblik
August 12, 2022
in Chronic Disease, Neurology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Prasinezumab had no meaningful effect on global or imaging measures of Parkinson’s disease progression.

2. Prasinezumab therapy was associated with increased infusion reactions compared to placebo.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Aggregated a-synuclein is a main factor in the pathogenesis of Parkinson’s disease. Prasinezumab was designed as a monoclonal antibody to bind aggregated a-synuclein at the C-terminal selectively. In phase one trials, Prasinezumab has been demonstrated to show brain penetration. Further, it has resulted in dose-dependent reductions from baseline free serum a-synuclein levels. However, there is a knowledge gap in understanding the efficacy and safety of low dose (1500mg) and high dose (4500 mg) Prasinezumab in patients with early-stage Parkinson’s disease. Overall, the present study found that treatment with Prasinezumab had no meaningful effect on global clinical or imaging measures of Parkinson’s disease progression. This study was limited by the planned censoring of data from participants when they started treatment for symptoms of Parkinson’s disease. The trial population was also not representative of the wider population of persons with Parkinson’s disease, as non-White, non-United States, and non-European populations were underrepresented. Nevertheless, the study’s findings are significant, as they demonstrate that Prasinezumab has no clinically meaningful effect on early-stage Parkinson’s disease progression.

Click to read the study in NEJM

Relevant Reading: Randomized Trial of Focused Ultrasound Subthalamotomy for Parkinson’s Disease

RELATED REPORTS

Early screening for emotional and cognitive issues may improve psychiatric outcomes for stroke patients

Artificial intelligence may assist in early detection of decreased ejection fraction on echocardiograms

2 Minute Medicine Rewind June 16, 2025

In-Depth [randomized control trial]: This randomized phase two trial assigned participants with early-stage Parkinson’s disease in a 1:1:1 ratio to receive either intravenous placebo, low-dose Prasinezumab, or high-dose Prasinezumab every four weeks for 52 weeks. Patients who had early-stage Parkinson’s disease, findings on dopamine transporter imaging with SPECT that were consistent with Parkinson’s, and no previous treatment for symptoms of Parkinson’s disease were eligible for the study. The primary outcome measure was the change from baseline to week 52 in the sum of scores of the Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS), with higher scores indicating greater impairment. Outcomes in the primary analysis were assessed via pairwise comparison and efficacy analyses. Based on the primary analysis, the mean changes in the MDS-UPDRS scores were 9.4+/-1.2 in the placebo group, 7.4+/-1.2 in the low-dose Prasinezumab group (difference versus placebo, -2.0; 80% Confidence Interval [CI], -4.2 to 0.2), and 8.8+/-1.2 in the high dose Prasinezumab group (difference versus placebo, -0.6; 80% CI -2.8 to 1.6). There was no significant difference between the Prasinezumab treatment groups and the placebo group in dopamine transporter levels on SPECT. Moreover, infusion reactions occurred in 19% of the low dose group and in 34% of the high dose Prasinezumab group. Overall, this study demonstrates that Prasinezumab has no significant nor clinically meaningful effect on global or imaging measures of Parkinson’s disease progression, suggesting it is not an effective therapy for preventing or slowing the progression of early-stage Parkinson’s disease.

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: a-synucleinAggregated a-synucleinchronic diseasedegenerative diseaseneurological diseaseneurologyParkinson’sParkinson’s DiseasePrasinezumab
Previous Post

Prior syncope presentation not associated with increased risk of motor vehicle collision

Next Post

Vitamin D deficiency may be associated with sleep disorders in children

RelatedReports

Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults
Neurology

Early screening for emotional and cognitive issues may improve psychiatric outcomes for stroke patients

June 20, 2025
Lisinopril and carvedilol reduce cardiotoxicity in breast cancer patients receiving trastuzumab and anthracyclines
Cardiology

Artificial intelligence may assist in early detection of decreased ejection fraction on echocardiograms

June 19, 2025
Survival greater in cervical cancer patients undergoing abdominal hysterectomy compared to minimally invasive techniques: the LACC trial
Weekly Rewinds

2 Minute Medicine Rewind June 16, 2025

June 16, 2025
Quick Take: The clinical effectiveness of sertraline in primary care and the role of depression severity and duration (PANDA): a pragmatic, double-blind, placebo-controlled randomized trial
Chronic Disease

Use of psychiatric medications may be associated with a higher risk of amyotrophic lateral sclerosis

June 12, 2025
Next Post
Parents with poor sleep quality report sleep problems in kids

Vitamin D deficiency may be associated with sleep disorders in children

Adalimumab aids in control of noninfectious uveitis

Daily disposable contact lenses may lower risk for Acanthamoeba keratitis

The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]

LI-RADS outlines standards for liver imaging studies assessing HCC [Classics Series]

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Early screening for emotional and cognitive issues may improve psychiatric outcomes for stroke patients
  • Artificial intelligence may assist in early detection of decreased ejection fraction on echocardiograms
  • #VisualAbstract: Tarlatamab Improves Survival in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.